50BA.F Bicycle Therapeutics plc

Healthcare Biotechnology Frankfurt Exchange
4.54 EUR
Close of Nov 12, 2026
2.94 6.20
Market cap
EUR 230M
P/E
-
P/B
0.50x
ROE
-32.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 50BA.F undervalued?

Graham number

The Graham number of Bicycle Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bicycle Therapeutics plc fundamental analysis

No fundamental analysis for Bicycle Therapeutics plc yet.

Bicycle Therapeutics plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin t…

Full company profile